Compare EH & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | DRTS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | China | Israel |
| Employees | 483 | 121 |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.5M | 641.6M |
| IPO Year | 2019 | N/A |
| Metric | EH | DRTS |
|---|---|---|
| Price | $9.37 | $10.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $22.47 | $8.67 |
| AVG Volume (30 Days) | 522.9K | ★ 740.1K |
| Earning Date | 05-26-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.23 | N/A |
| Revenue Next Year | $73.83 | $699.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.04 | $2.81 |
| 52 Week High | $20.44 | $10.85 |
| Indicator | EH | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.72 | 68.36 |
| Support Level | $9.15 | $6.59 |
| Resistance Level | $10.68 | N/A |
| Average True Range (ATR) | 0.42 | 0.90 |
| MACD | -0.06 | 0.22 |
| Stochastic Oscillator | 23.17 | 94.84 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.